GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $12.55 million. The enterprise value is $10.30 million.
Important Dates
The next estimated earnings date is Friday, March 27, 2026, after market close.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 26.65 million shares outstanding. The number of shares has increased by 68.81% in one year.
| Current Share Class | 26.65M |
| Shares Outstanding | 26.65M |
| Shares Change (YoY) | +68.81% |
| Shares Change (QoQ) | +42.17% |
| Owned by Insiders (%) | 1.47% |
| Owned by Institutions (%) | 4.42% |
| Float | 25.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.04 |
| P/TBV Ratio | 4.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.27
| Current Ratio | 3.27 |
| Quick Ratio | 1.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -356.99% and return on invested capital (ROIC) is -259.71%.
| Return on Equity (ROE) | -356.99% |
| Return on Assets (ROA) | -119.47% |
| Return on Invested Capital (ROIC) | -259.71% |
| Return on Capital Employed (ROCE) | -353.00% |
| Weighted Average Cost of Capital (WACC) | 11.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.33M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.69% in the last 52 weeks. The beta is 1.25, so GT Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -78.69% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 34.26 |
| Average Volume (20 Days) | 1,770,207 |
Short Selling Information
The latest short interest is 2.43 million, so 9.10% of the outstanding shares have been sold short.
| Short Interest | 2.43M |
| Short Previous Month | 2.11M |
| Short % of Shares Out | 9.10% |
| Short % of Float | 9.39% |
| Short Ratio (days to cover) | 1.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.59M |
| Pretax Income | -9.10M |
| Net Income | -9.33M |
| EBITDA | n/a |
| EBIT | -10.59M |
| Earnings Per Share (EPS) | -$3.29 |
Full Income StatementBalance Sheet
The company has $2.53 million in cash and n/a in debt, with a net cash position of $2.53 million or $0.09 per share.
| Cash & Cash Equivalents | 2.53M |
| Total Debt | n/a |
| Net Cash | 2.53M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 3.00M |
| Book Value Per Share | 0.50 |
| Working Capital | 3.00M |
Full Balance SheetCash Flow
| Operating Cash Flow | -11.36M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.36M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
